Results 31 to 40 of about 868 (155)
Use of Yttrium-90 Microspheres (Therasphere®) in a Patient with Unresectable Hepatocellular Carcinoma Leading to Liver Transplantation [PDF]
Liver Transplantation, 2005 Prior to therapy, model for end stage liver disease (MELD) scoring, diagnostic imaging and tumor staging were performed in a patient with T3 HCC. The patient received an orthotopic liver transplant (OLT) 42 days after treatment. The explant specimen showed complete necrosis of the target tumor.
Laura M, Kulik +5 more
openaire +2 more sources
Correlating serum alpha-fetoprotein in hepatocellular carcinoma with response to Yttrium-90 transarterial radioembolization with glass microspheres (TheraSphere™) [PDF]
HPB, 2020 Few studies have assessed the relationship between serum alpha-fetoprotein (AFP) and yttrium-90 (Y-90) radioembolization response in hepatocellular carcinoma (HCC). The objective of the study was to evaluate whether peri-procedural serum AFP was correlated with Y-90 therapy response in HCC.Patients undergoing Y-90 radioembolization with glass ...
Neal, Bhutiani +9 more
openaire +2 more sources
Utility of Quantitative Tc-MAA SPECT/CT for yttrium-Labelled Microsphere Treatment Planning: Calculating Vascularized Hepatic Volume and Dosimetric Approach. [PDF]
, 2011 International audienceObjectives. The aim of this study was to assess the effectiveness of SPECT/CT for volume measurements and to report a case illustrating the major impact of SPECT/CT in calculating the vascularized liver volume and dosimetry prior to
Marc Pracht +19 more
core +1 more source
, 2021 Introduction: TheraSphere® microspheres containing yttrium 90Y are among many radioembolization agents used clinically to reduce liver tumor burden, and their effects on cancer volume reduction are well-established.
Olga Antipova (177772) +11 more
core +1 more source
978 Prolonged Survival With Radioembolization Using Theraspheres in Unresectable HCC
American Journal of Gastroenterology, 2019 INTRODUCTION: Selective Internal Radiation Therapy (SIRT) with Yttrium 90 using glass beads (Theraspheres) is increasingly being used for the treatment of unresectable Hepatocellular carcinoma approved by the FDA as a Humanitarian Device (HUD exemption). We are presenting data on 70 patients at our center (out of 130) that have
Parvez Mantry +4 more
openaire +2 more sources
Hepatocellular Carcinoma—How to Determine Therapeutic Options
Hepatology Communications, Volume 4, Issue 3, Page 342-354, March 2020., 2020 Deciding on specific treatment strategies involves not only tumor stage, performance status, and severity of underlying liver disease, but additional factors such as biomarkers, organ availability, and radiographic tumor response to treatment. In this review, we present hepatocellular carcinoma (HCC) cases to highlight how to determine therapeutic ...
Neil Mehta
wiley +1 more source
Medical Physics, Volume 47, Issue 3, Page 1105-1114, March 2020., 2020 Purpose Prior to 90Y hepatic radioembolization, a dosage of 99mTc‐macroaggregated albumin (99mTc‐MAA) is administered to simulate the distribution of the 90Y‐loaded microspheres. This pretreatment procedure enables lung shunt estimation, detection of potential extrahepatic depositions, and estimation of the intrahepatic dose distribution.
Britt Kunnen +5 more
wiley +1 more source
Early experience of radioembolization using TheraSphere for the treatment of hepatocellular carcinoma secondary to the hepatitis B virus in Korea [PDF]
Journal of Vascular and Interventional Radiology, 2017 G Kim +7 more
openaire +2 more sources
Canadian Journal of Gastroenterology and Hepatology, Volume 2020, Issue 1, 2020., 2020 Background. Yttrium‐90 (Y‐90) can be an effective liver‐directed therapy for patients with metastatic neuroendocrine tumors (NETs), but population‐based data are limited. We characterized the use of Y‐90 in NET patients and identified factors associated with response. Methods.
Erica S. Tsang +9 more
wiley +1 more source